← Back to Search

Opioid Analgesic

A for Chronic Pain

Phase 2
Waitlist Available
Led By Andrew Rosenblum, PhD
Research Sponsored by National Institute on Drug Abuse (NIDA)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1, 2, 3, 4, 5 & 6 months
Awards & highlights

Study Summary

The purpose of this study is to develop and pilot test clinical guidelines for the use of buprenorphine for the treatment chronic pain among patients with substance abuse histories. Buprenorphine, an opioid medication, holds promise as a treatment of chronic pain because, compared to most other opioid analgesics, it has a high safety profile, a low level of physical dependence, and mild withdrawal symptoms on cessation. Moreover there are promising reports from Europe of its use as a skin patch to treat chronic pain as well as clinical reports in the U.S. that it may be effective when used sublingually (placed under the tongue). This study will test the sublingual formulation.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1, 2, 3, 4, 5 & 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1, 2, 3, 4, 5 & 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pain severity
Secondary outcome measures
Pain behaviors, psychiatric distress, drug use, side effects

Side effects data

From 2007 Phase 4 trial • 60 Patients • NCT00684073
8%
Fatigue
6%
Headache
6%
Hyperhidrosis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Subutex®/Suboxone®

Trial Design

1Treatment groups
Experimental Treatment
Group I: AExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Buprenorphine
FDA approved

Find a Location

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)Lead Sponsor
2,468 Previous Clinical Trials
2,619,309 Total Patients Enrolled
55 Trials studying Chronic Pain
82,920 Patients Enrolled for Chronic Pain
Beth Israel Medical CenterOTHER
70 Previous Clinical Trials
8,410 Total Patients Enrolled
2 Trials studying Chronic Pain
528 Patients Enrolled for Chronic Pain
Andrew Rosenblum, PhDPrincipal InvestigatorNDRI

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~2 spots leftby Apr 2025